Print Bookmark Email

Hopkins TB Fighters Make Esquire's “Best And Brightest” List

MEDIA CONTACT: Ekaterina Pesheva
EMAIL: epeshev1@jhmi.edu
PHONE: (410) 502-9433

December 04, 2007

Hidden in a lab, clad in plastic gowns, booties and gloves, poring over lung-tissue samples, Hopkins infectious disease specialists Jacques Grosset, Sanjay Jain, Gyanu Lamichhane and Eric Nuermberger don’t conjure up the image of those you would read about on the glossy pages of an upscale men’s magazine. But the four have landed spots on Esquire’s “Best and Brightest” list for 2007 for their work to find new cures for TB.

The rankings feature 36 revolutionaries, or, “36 reasons for hope,” among them scientists, doctors, artists, engineers and a free-speech advocate.

At the Hopkins Center for TB Research, Grosset, Jain, Lamichhane and Nuermberger are working to develop new treatments for TB and improve existing ones.

Grosset, 78, received his medical degree from the University of Paris. After contracting the disease at the age of 24, Grosset decided to study the deadly bacterium and devoted much of his subsequent work to testing and finding new treatments. He worked in his native France almost his entire career as well as in Algiers, a former French colony. Grosset’s work has illuminated much of what is known about TB drug therapy today. He joined Hopkins in 2002.

Jain, 32, a pediatrician and infectious disease specialist at Hopkins Children’s, went to medical school in New Delhi, India, a country where TB is endemic. Jain completed his pediatric residency at Floating Hospital for Children in Boston and his fellowship in pediatric infectious diseases at Hopkins. Jain leads a project to design a system that visually tracks the TB bacterium in the body and monitors its response to drug treatments. Jain also studies central nervous system TB, which disproportionately affects younger children.

Lamichhane, 32, a microbiologist, received his Ph. D. from Hopkins and was a visiting fellow at the University of Toronto. He currently studies the genetic underpinnings of TB, and together with his colleague William Bishai, M.D., Ph. D., has identified several genes involved in TB that may serve as new targets for drug therapy.

Nuermberger, 37, an infectious disease specialist who also has an appointment in International Health at the Johns Hopkins Bloomberg School of Public Health, trained at Vanderbilt University. He completed his residency and fellowship in Infectious Diseases at Hopkins. Nuermberger works with mice and other models to develop new, shorter drug regimens.

Founded in 1912 as the children's hospital at Johns Hopkins, the Johns Hopkins Children's Center offers one of the most comprehensive pediatric medical programs in the country, with more than 92,000 patient visits and nearly 9,000 admissions each year. The Johns Hopkins Children's Center is Maryland's largest children's hospital and the only state-designated Trauma Service and Burn Unit for pediatric patients. It has recognized Centers of Excellence in dozens of pediatric subspecialties, including allergy, cardiology, cystic fibrosis, gastroenterology, nephrology, neurology, neurosurgery, oncology, pulmonary, and transplant. For more information, visit www.hopkinschildrens.org.